Proposed Data Collection Submitted for Public Comment and Recommendations, 1493-1495 [2025-00164]
Download as PDF
<![CDATA[
1493
Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices
gauge progress in meeting NBCCEDP
program goals and monitor
implementation activities, evaluate
outcomes, and identify awardee
technical assistance needs. In addition,
findings will inform program
improvement and help identify
successful activities that need to be
maintained, replicated, or expanded.
CDC requests OMB approval for three
years and for an estimated 1,162 annual
burden hours. Participation is required
for NBCCEDP awardees. There are no
costs to respondents other than their
time.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
NBCCEDP Recipients .....................................
Annual NBCCEDP Survey .............................
NBCCEDP Clinic-level Information Collection
Instrument—Breast.
NBCCEDP Clinic-level Information Collection
Instrument—Cervical.
Quarterly Program Update .............................
Service Delivery Projection Worksheet ..........
MDEs ..............................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2025–00161 Filed 1–7–25; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–25–25CH; Docket No. CDC–2024–
0102]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Combating
Antimicrobial Resistant Gonorrhea and
Other STIs (CARGOS). CARGOS is a
comprehensive strategy designed to
streamline and improve the
coordination of Antimicrobial
Resistance (AR) surveillance and
preparedness and response activities
focused on Neisseria gonorrhoeae (GC)
and expand capacity to include other
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
Number of
respondents
Type of respondent
VerDate Sep<11>2014
17:50 Jan 07, 2025
Jkt 265001
STIs with emerging AR in the United
States.
CDC must receive written
comments on or before March 10, 2025.
ADDRESSES: You may submit comments
identified by Docket No. CDC–2024–
0102 by either of the following methods:
b Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
b Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov. Please note:
Submit all comments through the
Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7118; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
DATES:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(in hrs)
71
71
1
6
46/60
40/60
71
6
40/60
71
71
71
4
1
2
32/60
29/60
150/60
information, including each new
proposed collection, each proposed
extension of the existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of collecting
information on those to respond,
including using appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic responses;
and
5. Assess information collection costs.
Proposed Project
Combating Antimicrobial Resistant
Gonorrhea and Other STIs (CARGOS)—
New—National Center for HIV, Viral
Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The purpose of the proposed
Combating Antimicrobial Resistant
E:\FR\FM\08JAN1.SGM
08JAN1
1494
Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Gonorrhea and Other STIs (CARGOS)
data collection is to: (1) strengthen local
epidemiologic capacity to detect,
monitor, and respond to AR in STIs; (2)
improve coordination of AR in STI
preparedness and outbreak response
activities; (3) enhance local laboratory
testing for surveillance, reporting, and
response; and (4) enhance coordination
between epi-lab-health information
technology for public health action.
This information collection is important
because: (1) effective treatment of
gonorrhea is critical to gonorrhea
control and prevention; (2) untreated or
inadequately treated gonorrhea can
cause serious reproductive health
complications, such as infertility; (3)
Neisseria gonorrhoeae (the bacterium
that causes gonorrhea) has consistently
demonstrated the ability to develop
resistance to the antibiotics used for
treatment and may be developing
resistance to the last remaining
treatment option recommended by CDC;
and (4) antibiotic-resistant gonorrhea is
extremely difficult to detect without
enhanced surveillance and public
health activities, such as CARGOS,
because healthcare providers rarely
perform or have access to resistance
testing for individual patients. CARGOS
will support rapid detection of resistant
gonorrhea, get actionable information
into the hands of healthcare providers
(to support appropriate treatment of
individual patients) and local health
departments (to support rapid public
health response to slow the spread of
resistant infections in the community),
and support multiple national public
health strategies including the 2020–
2025 National Action Plan for
Combating Antibiotic-Resistant Bacteria
(CARB) and STI National Strategic Plan
for the United States 2021–2025.
Jurisdictions participating in
CARGOS applied as part of a
competitive process and will participate
voluntarily. As an overview of
CARGOS, healthcare providers at
participating clinics will collect
specimens for N. gonorrhoeae culture
testing from men and women seeking
care for gonorrhea. Specimens that
demonstrate N. gonorrhoeae (called
‘‘isolates’’) will undergo antibiotic
resistance testing at the local public
health laboratory. Detection of
resistance is rapidly communicated by
the laboratory staff to the healthcare
provider and health department to
initiate a field investigation. The patient
(from whom the resistant specimen was
taken) will be interviewed to obtain
demographics, clinical and risk factor
information. For cases of gonorrhea of
public health significance, recent sexual
contacts of those cases will be
interviewed by the health department
and tested for gonorrhea. The
participating health departments will
collect and transmit to CDC
demographic and clinical data about
persons tested for and diagnosed with
gonorrhea in the participating clinics,
results of local antibiotic resistance
testing, and information about field
investigations. None of the data
transmitted to CDC will contain any
personally identifiable information.
These data will be used by CDC to
monitor and improve understanding of
resistance and identify scalable,
effective approaches to prevent the
spread of resistance. Data will be
transmitted through CDC’s Secure
Access Management Services (SAMS).
SAMS is an approved federal
information technology system that
provides authorized and validated users
secure and encrypted access to CDC file
transfer applications. The encrypted
data will be stored in a secure CDC
server with strictly controlled and
restricted access rights. Isolates will be
shipped each month to one of four
Antibiotic Resistance Regional
Laboratory Network (ARLN) laboratories
for confirmatory antibiotic susceptibility
testing and molecular characterization.
Under the CARGOS protocol, local
CARGOS data managers from each of
the funded jurisdictions will abstract
Number of
respondents
STD clinic data for patients tested for
gonorrhea, receive resistance testing
laboratory results from local public
health laboratories, abstract data about
field investigations, and will merge the
data. Every month, the local CARGOS
data manager will clean the data,
remove personally identifiable
information, and transmit the data to
CDC. CDC estimates these data
processes will take eight hours every
month. Annually, the local CARGOS
data manager will send a final
cumulative data file for a total of 12 data
transmissions/responses.
Microbiologists at public health
laboratories from each funded
jurisdictions will conduct antibiotic
resistance testing on all N. gonorrhoeae
isolates on approximately 700 isolates
each year (600 clinical isolates and 100
control strains; each test is
approximately 10 minutes). Every
month, a laboratory data manager will
abstract test results and securely send
the datafile to the local CARGOS data
manager. We estimate that laboratory
data managers will spend approximately
one hour each time they abstract, clean,
and transmit project data.
Health department staff will interview
any person diagnosed with antibioticresistant gonorrhea or have a case of
gonorrhea of public health significance
(index case) and his/her sexual contacts.
On average, two drug-resistant isolates
are identified annually. These isolates
will spur field investigations, which
will result in two additional interviews
each month. CDC estimates a total of 48
interviews will occur annually at each
site, for a total of 960 interviews each
year across the funded sites. Each
interview will take approximately 30
minutes.
CDC requests OMB approval for an
estimated 3,875 annual burden hours.
Respondents receive federal funds to
participate in this project. There are no
additional costs to respondents other
than their time.
Number of
responses per
respondent
Average
burden per
response
(hours)
Total burden
hours
Type of respondent
Form name
Public Health Laboratory Microbiologist.
Public Health Laboratory Data Manager.
Local CARGOS data manager/epidemiologist.
Gonorrhea Patients and Sexual Contacts.
Attachment 3A ..................................
19
700
10/60
2,217
Attachment 3A ..................................
19
6
1
114
Attachments 3A, 3B, 3C ..................
19
7
8
1,064
Attachment 3C .................................
960
1
0.5
480
Total ...........................................
...........................................................
........................
........................
........................
3,875
VerDate Sep<11>2014
17:50 Jan 07, 2025
Jkt 265001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
E:\FR\FM\08JAN1.SGM
08JAN1
Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2025–00164 Filed 1–7–25; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60–Day–25–0666; Docket No. CDC–2025–
0001]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Pathogens of High Consequence,
which assesses the incidence and
prevalence of select high consequence
pathogens of public health importance
in acute care hospitals. In addition to
the nine diseases approved for
collection, the following three
additional diseases are being added to
the form: Influenza A (H5), Marburg,
and Oropouche.
DATES: CDC must receive written
comments on or before March 10, 2025.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2025–
0001 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:50 Jan 07, 2025
Jkt 265001
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
National Healthcare Safety Network
(NHSN) (OMB Control No. 0920–0666,
Exp. 12/31/2027)—Revision—
Information Collection Request—
National Center for Emerging and
Zoonotic Infection Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
1495
Background and Brief Description
The Division of Healthcare Quality
Promotion (DHQP), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC) collects
data from healthcare facilities in the
National Healthcare Safety Network
(NHSN) under OMB Control Number
0920–0666. NHSN provides facilities,
health departments, states, regions, and
the nation with data necessary to
identify problem areas, measure the
progress of prevention efforts, and
ultimately eliminate healthcareassociated infections (HAIs) nationwide.
NHSN also allows healthcare facilities
to track blood safety errors and various
HAI prevention practice methods such
as healthcare personnel influenza
vaccine status and corresponding
infection control adherence rates.
Enrollment in NHSN has
continuously increased, with over
37,000 actively reporting healthcare
facilities across the U.S. Of the total
enrolled healthcare facilities, there are
over 6,000 acute care facilities. NHSN
currently has eight components, and the
collection of information is authorized
by the Public Health Service Act (42
U.S.C. 242b, 242k, and 242m (d)),
(Attachment A1–A3). Data reported
under NHSN’s Patient Safety
Component are used to determine the
magnitude of the healthcare-associated
adverse events and trends in the rates of
the events, in the distribution of
pathogens, and in the adherence to
prevention practices. Data will help
detect changes in the epidemiology of
adverse events resulting from new
medical therapies and changing patient
risks. Additionally, reported data is
being used to describe the epidemiology
of antimicrobial use and resistance and
to better understand the relationship of
antimicrobial therapy to this rising
problem.
NHSN’s data is used to aid in the
tracking of HAIs and guide infection
prevention activities/practices that
protect patients. The Centers for
Medicare and Medicaid Services (CMS)
and other payers use these data to
determine incentives for performance at
healthcare facilities across the U.S. and
surrounding territories, and members of
the public may use some protected data
to inform their selection among
available providers.Each of these parties
is dependent on the completeness and
accuracy of the data. CDC and CMS
work closely and are fully committed to
ensuring complete and accurate
reporting, which are critical for
protecting patients and guiding
E:\FR\FM\08JAN1.SGM
08JAN1
]]>Agencies
[Federal Register Volume 90, Number 5 (Wednesday, January 8, 2025)]
[Notices]
[Pages 1493-1495]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00164]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-25-25CH; Docket No. CDC-2024-0102]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled Combating Antimicrobial Resistant Gonorrhea and Other STIs
(CARGOS). CARGOS is a comprehensive strategy designed to streamline and
improve the coordination of Antimicrobial Resistance (AR) surveillance
and preparedness and response activities focused on Neisseria
gonorrhoeae (GC) and expand capacity to include other STIs with
emerging AR in the United States.
DATES: CDC must receive written comments on or before March 10, 2025.
ADDRESSES: You may submit comments identified by Docket No. CDC-2024-
0102 by either of the following methods:
[squ] Federal eRulemaking Portal: www.regulations.gov. Follow the
instructions for submitting comments.
[squ] Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov. Please note: Submit all comments through the
Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of the existing collection
of information, and each reinstatement of previously approved
information collection before submitting the collection to the OMB for
approval. To comply with this requirement, we are publishing this
notice of a proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of collecting information on those to
respond, including using appropriate automated, electronic, mechanical,
or other technological collection techniques or other forms of
information technology, e.g., permitting electronic responses; and
5. Assess information collection costs.
Proposed Project
Combating Antimicrobial Resistant Gonorrhea and Other STIs
(CARGOS)--New--National Center for HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the proposed Combating Antimicrobial Resistant
[[Page 1494]]
Gonorrhea and Other STIs (CARGOS) data collection is to: (1) strengthen
local epidemiologic capacity to detect, monitor, and respond to AR in
STIs; (2) improve coordination of AR in STI preparedness and outbreak
response activities; (3) enhance local laboratory testing for
surveillance, reporting, and response; and (4) enhance coordination
between epi-lab-health information technology for public health action.
This information collection is important because: (1) effective
treatment of gonorrhea is critical to gonorrhea control and prevention;
(2) untreated or inadequately treated gonorrhea can cause serious
reproductive health complications, such as infertility; (3) Neisseria
gonorrhoeae (the bacterium that causes gonorrhea) has consistently
demonstrated the ability to develop resistance to the antibiotics used
for treatment and may be developing resistance to the last remaining
treatment option recommended by CDC; and (4) antibiotic-resistant
gonorrhea is extremely difficult to detect without enhanced
surveillance and public health activities, such as CARGOS, because
healthcare providers rarely perform or have access to resistance
testing for individual patients. CARGOS will support rapid detection of
resistant gonorrhea, get actionable information into the hands of
healthcare providers (to support appropriate treatment of individual
patients) and local health departments (to support rapid public health
response to slow the spread of resistant infections in the community),
and support multiple national public health strategies including the
2020-2025 National Action Plan for Combating Antibiotic-Resistant
Bacteria (CARB) and STI National Strategic Plan for the United States
2021-2025.
Jurisdictions participating in CARGOS applied as part of a
competitive process and will participate voluntarily. As an overview of
CARGOS, healthcare providers at participating clinics will collect
specimens for N. gonorrhoeae culture testing from men and women seeking
care for gonorrhea. Specimens that demonstrate N. gonorrhoeae (called
``isolates'') will undergo antibiotic resistance testing at the local
public health laboratory. Detection of resistance is rapidly
communicated by the laboratory staff to the healthcare provider and
health department to initiate a field investigation. The patient (from
whom the resistant specimen was taken) will be interviewed to obtain
demographics, clinical and risk factor information. For cases of
gonorrhea of public health significance, recent sexual contacts of
those cases will be interviewed by the health department and tested for
gonorrhea. The participating health departments will collect and
transmit to CDC demographic and clinical data about persons tested for
and diagnosed with gonorrhea in the participating clinics, results of
local antibiotic resistance testing, and information about field
investigations. None of the data transmitted to CDC will contain any
personally identifiable information. These data will be used by CDC to
monitor and improve understanding of resistance and identify scalable,
effective approaches to prevent the spread of resistance. Data will be
transmitted through CDC's Secure Access Management Services (SAMS).
SAMS is an approved federal information technology system that provides
authorized and validated users secure and encrypted access to CDC file
transfer applications. The encrypted data will be stored in a secure
CDC server with strictly controlled and restricted access rights.
Isolates will be shipped each month to one of four Antibiotic
Resistance Regional Laboratory Network (ARLN) laboratories for
confirmatory antibiotic susceptibility testing and molecular
characterization.
Under the CARGOS protocol, local CARGOS data managers from each of
the funded jurisdictions will abstract STD clinic data for patients
tested for gonorrhea, receive resistance testing laboratory results
from local public health laboratories, abstract data about field
investigations, and will merge the data. Every month, the local CARGOS
data manager will clean the data, remove personally identifiable
information, and transmit the data to CDC. CDC estimates these data
processes will take eight hours every month. Annually, the local CARGOS
data manager will send a final cumulative data file for a total of 12
data transmissions/responses.
Microbiologists at public health laboratories from each funded
jurisdictions will conduct antibiotic resistance testing on all N.
gonorrhoeae isolates on approximately 700 isolates each year (600
clinical isolates and 100 control strains; each test is approximately
10 minutes). Every month, a laboratory data manager will abstract test
results and securely send the datafile to the local CARGOS data
manager. We estimate that laboratory data managers will spend
approximately one hour each time they abstract, clean, and transmit
project data.
Health department staff will interview any person diagnosed with
antibiotic-resistant gonorrhea or have a case of gonorrhea of public
health significance (index case) and his/her sexual contacts. On
average, two drug-resistant isolates are identified annually. These
isolates will spur field investigations, which will result in two
additional interviews each month. CDC estimates a total of 48
interviews will occur annually at each site, for a total of 960
interviews each year across the funded sites. Each interview will take
approximately 30 minutes.
CDC requests OMB approval for an estimated 3,875 annual burden
hours. Respondents receive federal funds to participate in this
project. There are no additional costs to respondents other than their
time.
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Form name Number of responses per per response Total burden
respondents respondent (hours) hours
----------------------------------------------------------------------------------------------------------------
Public Health Laboratory Attachment 3A... 19 700 10/60 2,217
Microbiologist.
Public Health Laboratory Data Attachment 3A... 19 6 1 114
Manager.
Local CARGOS data manager/ Attachments 3A, 19 7 8 1,064
epidemiologist. 3B, 3C.
Gonorrhea Patients and Sexual Attachment 3C... 960 1 0.5 480
Contacts.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 3,875
----------------------------------------------------------------------------------------------------------------
[[Page 1495]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2025-00164 Filed 1-7-25; 8:45 am]
BILLING CODE 4163-18-P
